DXCM

Add to Watchlist

Advanced Chart

0.000

0.000(0.000%)

Overview
Forecast
Valuation

High

85.710

Open

84.780

VWAP

85.04

Vol

3.35M

Mkt Cap

33.20B

Low

84.230

Amount

284.79M

EV/EBITDA(TTM)

36.50

Total Shares

397.68M

33.26B

EV/OCF(TTM)

34.50

P/S(TTM)

8.44

DexCom, Inc. is a medical device company. The Company enables people to take real-time control of health through continuous glucose monitoring (CGM) systems. The Company is engaged in diabetes care technology. Based on the needs of users, caregivers, and providers, the Company works to simplify and improve diabetes management around the world. The Company is primarily focused on the design, development, and commercialization of CGM, systems for the management of diabetes by patients, caregivers, and clinicians around the world. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Dexcom Stelo is designed specifically for people with type II diabetes who do not use insulin and are not at risk for hypoglycemia. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

1.12B

+11.86%

0.448

+4.21%

1.17B

+17.66%

0.566

+25.85%

1.28B

+14.65%

0.689

+53.14%

Estimates Revision

The market is revising Downward the revenue expectations for DexCom, Inc. (DXCM) for FY2025, with the revenue forecasts being adjusted by -0.14% over the past three months. During the same period, the stock price has changed by -4.08%.

Revenue Estimates for FY2025

Revise Downward

-0.14%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.47%

In Past 3 Month

Stock Price

Go Down

-4.08%

In Past 3 Month

19 Analyst Rating

18.03% Upside

Wall Street analysts forecast DXCM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DXCM is 99.94 USD with a low forecast of 82.00 USD and a high forecast of 115.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

17 Buy

2 Hold

0 Sell

Strong Buy

18.03% Upside

Current: 84.670

Low

82.00

Averages

99.94

High

115.00

18.03% Upside

Current: 84.670

Low

82.00

Averages

99.94

High

115.00

Barclays

Matt Miksic

Hold

Maintains

$90 → $93

2025-05-05

New

Reason

Barclays

Matt Miksic

Price Target

$90 → $93

2025-05-05

New

Maintains

Hold

Reason

Barclays raised the firm's price target on DexCom to $93 from $90 and keeps an Equal Weight rating on the shares. The firm made "elatively minor changes" to its model to reflect the company's Q1 results and revised 2025 guidance.

Baird

Jeff Johnson

Buy

Maintains

$115 → $105

2025-05-02

Reason

Baird

Jeff Johnson

Price Target

$115 → $105

2025-05-02

Maintains

Buy

Reason

Baird lowered the firm's price target on DexCom to $105 from $115 and keeps an Outperform rating on the shares. The firm updated its model following mixed Q1 results where momentum was encouraging and the setup is good for second half 2025.

Piper Sandler

Matt O'Brien

Buy

Maintains

$100 → $90

2025-05-02

Reason

Piper Sandler

Matt O'Brien

Price Target

$100 → $90

2025-05-02

Maintains

Buy

Reason

Canaccord Genuity

William Plovanic

Strong Buy

Maintains

$103 → $106

2025-05-02

Reason

Canaccord Genuity

William Plovanic

Price Target

$103 → $106

2025-05-02

Maintains

Strong Buy

Reason

Canaccord raised the firm's price target on DexCom to $106 from $103 and keeps a Buy rating on the shares. The firm said they reported a good Q1, beating total and US revenue estimates, while short of OUS estimates but showing strong organic growth OUS.

Mizuho

Anthony Petrone

Buy

Initiates

$85

2025-04-10

Reason

Mizuho

Anthony Petrone

Price Target

$85

2025-04-10

Initiates

Buy

Reason

Mizuho analyst Anthony Petrone initiated coverage of DexCom with an Outperform rating and $85 price target. The firm cites its positive survey data for continued continuous glucose monitoring adoption coupled with "bullish" physician feedback for DexCom's flagship G7 adoption as well as Stelo in the consumer markets for the Outperform rating. Physicians are forecasting the U.S. continued continuous glucose monitoring market to expand 20% over the next two years with the 15-day G7 sensor poised to gain share among various type 2 diabetic populations, the analyst tells investors in a research note. Mizuho has a $100 "bull case" for DexCom shares, which considers faster G7 stabilization and broader Stelo adoption scenarios.

Citigroup

Joanne Wuensch

Strong Buy

Maintains

$101 → $104

2025-03-04

Reason

Citigroup

Joanne Wuensch

Price Target

$101 → $104

2025-03-04

Maintains

Strong Buy

Reason

Citi raised the firm's price target on DexCom to $104 from $101 and keeps a Buy rating on the shares. The firm adjusted medical technology models post the Q4 reports. The prints "were largely benign compared to a chaotic" Q2 and Q3, the analyst tells investors in a research note.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Dexcom Inc (DXCM.O) is 38.79, compared to its 5-year average forward P/E of 102.97. For a more detailed relative valuation and DCF analysis to assess Dexcom Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Undervalued

5Y Average PE

102.97

Current PE

38.79

Overvalued PE

148.81

Undervalued PE

57.13

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Undervalued

5Y Average EV/EBITDA

55.35

Current EV/EBITDA

22.43

Overvalued EV/EBITDA

82.47

Undervalued EV/EBITDA

28.22

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

12.82

Current PS

7.01

Overvalued PS

16.93

Undervalued PS

8.72